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Abstract
Background: Treacher Collins syndrome (TCS) is one of the most severe autosomal dominant congenital disorders
of craniofacial development and shows variable phenotypic expression. TCS is extremely rare, occurring with an
incidence of 1 in 50.000 live births. The TCS distinguishing characteristics are represented by down slanting
palpebral fissures, coloboma of the eyelid, micrognathia, microtia and other deformity of the ears, hypoplastic
zygomatic arches, and macrostomia. Conductive hearing loss and cleft palate are often present. TCS results from
mutations in the TCOF1 gene located on chromosome 5, which encodes a serine/alanine-rich nucleolar phospho-
protein called Treacle. However, alterations in the TCOF1 gene have been implicated in only 81-93% of TCS cases.
Methods: In this study, the entire coding regions of the TCOF1 gene, including newly described exons 6A and
16A, were sequenced in 46 unrelated subjects suspected of TCS clinical indication.
Results: Fifteen mutations were reported, including twelve novel and three already described in 14 sporadic
patients and in 3 familial cases. Moreover, seven novel polymorphisms were also described. Most of the mutations
characterised were microdeletions spanning one or more nucleotides, in addition to an insertion of one nucleotide
in exon 18 and a stop mutation. The deletions and the insertion described cause a premature termination of
translation, resulting in a truncated protein.
Conclusion: This study confirms that almost all the TCOF1 pathogenic mutations fall in the coding region and lead
to an aberrant protein.
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Background
Treacher Collins syndrome (TCS; OMIM #154500) is an
autosomal dominant disorder that affects the craniofa-
cial development during early embryogenesis [1]. TCS is
characterized by bilaterally symmetric features, including
downward slanting palpebral fissures and colobomata of
the lower eyelids, hypoplasia of the midfacial bones,
cleft palate, and abnormal development of the external/
middle ear that often leads to conductive hearing loss
[2-4]. TCS occurs with an incidence of 1/50.000 and
more than 60% of TCS cases has no previous family his-
tory and arises as the result of de novo mutations [5].
The syndrome is caused by mutations in the TCOF1
gene (OMIM #606847), which encodes the nucleolar
phosphoprotein Treacle that may serve as a link
between rDNA gene transcription and pre-rRNA pro-
cessing [6]. Recently, Dauwerse et al. detected mutations
in genes encoding subunits of RNA polymerases I and
III (POLR1C and POLR1D) in Treacher Collins patients
[7].
Thus far, most of the 200 disease-causing mutations
described are deletions, insertions and nonsense, distrib-
uted along 28 exons [8]. Two additional exons have
been reported: exon 6A, included in the most common
isoform, and exon 16A, included in a minor isoform [9].
The mutations observed in TCS are predominantly
sporadic, and the vast majority results in the introduc-
tion of a premature termination codon that can lead to
the truncation of protein or to nonsense-mediated
mRNA decay [10,11]. This suggests in the developmen-
tal anomalies result from haploinsufficiency of TCOF1.
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t h o u g h tt ob ev e r yh i g h ;h o w e v e r ,e x t r e m ei n t e r -a n d
intra- familial phenotypic variation is reported [12].
In the present study, we screened 46 patients with a
clinical diagnosis of TCS, by sequencing the entire
TCOF1 coding sequence together with the splice junc-
tions. As result, 12 novel and 3 already reported muta-
tions were characterised together with 7 novel and 13
known polymorphisms.
Methods
Patients
46 patients with a clinical diagnosis of TCS were
recruited through several European Medical Institutes
since 2002. In particular, the patients were evaluated at
the University of Torino, Napoli, Rome Tor Vergata and
“La Sapienza”, University of Aquila, Ospedali Galliera of
Genova, IRCCS Casa Sollievo della Sofferenza at San
Giovanni Rotondo, Pediatric Department of SS. Pietro e
Paolo Hospital at Borgosesia, Pediatric Department of
the Bolzano Hospital, “Gaetano Rummo” Hospital at
Benevento, Clinica Mangiagalli at Milano, S. Pietro Hos-
pital at Rome, IRCCS “Ass. Oasi Maria SS” at Troina
(Italy), GENDIA lab (Antwerp, Belgium), Egas Moniz
Hospital (Lisbon, Portugal), Centre Hospitalier Universi-
taire de Rennes (France). Three patients have one parent
with similar TCS features, while the other 43 cases
haven’t a family history. The major clinical features of
TCS were recognized in all patients. After informed
consent was obtained from patients or their families,
blood samples were collected.
Mutational analysis
Genomic DNA was obtained from peripheral blood sam-
ples using EZ1 DNA Blood 200 μl purification kit (Qia-
gen, GmbH, Germany). Coding regions and intron/exon
boundaries of the TCOF1 gene were amplified in 28 reac-
tions using specific primers [13]. For exons 6A, 10, 16A,
24, and 25 specific primers were self designed (Table 1).
PCR amplification was performed in a 25 μl reaction
volume containing 2.5 U AmpliTaq Gold™ DNA poly-
merase (Applied Biosystems, Foster City, CA), 1X reac-
tion buffer (10 mM Tris HCl pH 8.3, 50 mM KCl, 2.5
mM MgCl2), 200 μM of each deoxyribonucleoside
triphosphate (dNTPs) and 0.2 mM each of primers
using a PTC 100 thermocycler (MJ Research, Inc. Wal-
tham, MA, USA).
A 10-minute denaturation step at 94°C was followed
by 30 cycles at 94°C for 30 seconds, annealing tem-
perature was performed, for each primer, 30 seconds
at 52.5-62°C, and extending for 30 sec at 72°C; the
reaction was completed by a final extension for 7 min-
utes at 72°C.
PCR products were purified by digestion with Antartic
Phosphatase and Exonuclease I (New England BioLabs
Inc.) and were sequenced in both directions using the
Applied Biosystem Big Dye Terminator v3.1 Cycle
sequencing kit.
New mutations were not found in 100 normal chro-
mosomes by sequencing.
Nucleotide and Aminoacid numbering
All mutations were named considering the genomic
reference [NT_029289] and the cDNA that corresponds
to the major treacle isoform [NM_001135243.1] [14].
Mutation nomenclature is based on HGVS nomencla-
ture guidelines [http://www.hgvs.org/mutnomen] [15].
In silico tools
The splice predictor software program, NNSplice ver-
sion 0.9 [http://www.fruitfly.org/seq_tools/splice.html],
was used for an initial approach to novel variant (c.
IVS16A-30G®A) suspected of causing aberrant RNA
processing of the TCOF1 gene. The ESE finder 2.0 pro-
gram [http://rulai.cshl.edu/tools/ESE2/] was used to pre-
dict hypothetical splicing enhancer in mutated c.
IVS16A-30G®A sequence.
Results
The TCOF1 gene analysis was carried out on the 46
TCS European patients by direct sequencing of 28 PCR
genomic fragments encompass i n gt h ec o m p l e t ec o d i n g
sequence and splice sites. We detected 15 different
TCOF1 mutations in 17 patients (Table 2 Figure 1), 12
new and 3 already described.
Considering the already known mutations, the 5-bp
deletion, c.4366_4370delGAAAA, in exon 24 (Figure
1A), was the most frequent mutation observed in this
study (3/17, 17%) (Patient TCS 15,16 and 17). In the
same exon (patient TCS 14), we identified the already
known frameshift mutation c.4359_4363delAAAAA
(Figure 1B). Both the mutations identified fall within the
TCOF1 mutation hot spot rich in 18 Lysine residues.
Other microdeletions have already been described in
this region [8,11,16-18].
The other known mutation is a 2 bp deletion,
c.1639_1640delAG (patient TCS 4), localized in exon 10
(Figure 1C) [8,13].
Table 1 Primers self-designed for TCOF1 gene
amplification and sequencing
FORWARD REVERSE
Ex 6A TTTATCAACTGCTGAAGCCCC ATAGTCCTCCCTCTCCCCAAC
Ex 10 CTGAACCTAGAGCCCTGTGGG AGACAGAGTCCCAGAGTGAGG
Ex 16A TGGAAACCAGAGTGCCTGAG TGATCCTGCAGCATCTGCAG
Ex 24 GCACCTCCCAACATTGAC GAACCAGGTCTGGGTGT
Ex 25 TCACTAGTCCTCAGGAGGT CTGCCTGGCTCTCTGGGA
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Page 2 of 6A total of 12 novel disease-causative mutations were
found in 2 familial cases and in 10 sporadic TCS
patients. These consist of 10 microdeletions (sized 1/15
nucleotides), one single-base duplication, and one non-
sense mutation. All deletions and insertion cause a fra-
meshift and produce a truncated protein.
The first reported pathogenic microdeletion was a
c.519delT in exon 5 (patient TCS 2) (Figure 1D) leading
to formation of a stop codon 46 aminoacids later. This
alteration was not found in the patient’s parents. Patient
TCS 5 was found to bear a de novo truncating mutation,
c.1581delG, in exon 10 (Figure 1E) that introduces a
premature stop codon 69 aminoacids later.
Two alterations were identified in exons 15 and 16,
that encode repetitive motifs. The former,
c.2626_2627delGA in exon 15 (Figure 1F), was identified
in patient TCS 8 and causes the formation of a stop
codon two aminoacids later. The latter, c.2831delA (Fig-
ure 1G), identified in the exon 16 of patient TCS 9,
causes a frameshift.
Another proband (TCS 12) was heterozygous for the
de novo c.3700_3704delACTCT mutation in exon 22
(Figure 1H).
The sequence analysis of a DNA sample obtained
from patient TCS 10 identified the c.3118_3119dupG
mutation in exon 18 (Figure 1I). Analysis of the relatives
indicated that this duplication was also present in the
affected father and brother.
Two more TCOF1 variations were found in patient
TCS 7. The first one was a single base sostitution,
c.2924C > T, in exon 17, determining the aminoacidic
change p.P975L. The other one was a 2 bp deletion,
c.2285_2286delCT in exon 13 (Figure 1J), wich results
in a frameshift and premature stop codon. Neither
abnormality was found in 140 and 100 healty chromo-
somes, respectively, indicating that they were not com-
mon polymorphisms.
Analysis of TCS 7’s normal parents DNA showed the
mother was a carrier of c.2924C > T. Neither of parents
showed the 2 bp deletion. Thus, it was indicated that
the 2 bp deletion, disrupting protein translation, is prob-
ably the causative mutation.
In the TCS 11 patient, a truncating mutation of 8
bases c.3456_3463delTTCTTCAG (Figure 1K) was
found in exon 20, causing a frameshift resulting in a
stop codon four codons later. The same kind of muta-
tion was found in TCS 6 patient in exon 12. A microde-
letion of one single base c.1973delC (Figure 1L) with a
stop codon 52 codons later.
In patient TCS 13 a nonsense mutation c.4231C > T
( F i g u r e1 M )w a sf o u n d .T h i sp a t h o g e n e t i cv a r i a t i o n
occurred in exon 23B causing a stop codon (p.Q1411X).
In patient TCS 1 a small deletion was found. It was a
truncating mutation of the last 2 nucleotides of exon 3,
c.303_304delCA (Figure 1N), causing a stop codon 73
codons later. Actually, the deletion involves the first 13
nucleotides of intron 3 (IVS3+13delGTAA-
GAGCCTTGC), too.
Finally, we detected a one bp deletion c.599delG in
patient TCS 3 (Figure 1O). It was a familial case, as we
Table 2 Pathogenic mutations in TCS patients
PATIENT GEOGRAPHIC
ORIGIN
EXON cDNA MAJOR ISOFORM MUTATION PROTEIN MUTATION OCCURRENCE REFERENCE
TCS 1 caucasian 3 c.303_304delCA p.A101Afsx73 Sporadic In this study
TCS 2 caucasian 5 c.519delT p.T173Tfsx46 Sporadic In this study
TCS 3 caucasian 6 c.599delG p.S200Tfsx19 Familial In this study
TCS 4 caucasian 10 c.1639_1640delAG p.S547Qfsx2 Sporadic [13]
TCS 5 caucasian 10 c.1581delG p.G587Gfsx69 Sporadic In this study
TCS 6 caucasian 12 c.1973delC p.P658Lfsx53 Sporadic In this study
TCS 7 caucasian 13 c.2285_2286delCT p.S762fs Sporadic In this study
TCS 8 caucasian 15 c.2626_2627delGA p.D876Qfsx2 Sporadic In this study
TCS 9 caucasian 16 c.2831delA p.E944Efsx6 Sporadic In this study
TCS 10 caucasian 18 c.3118_3119dupG p.A1040Gfx47 Familial In this study
TCS 11 caucasian 20 c.3456_63delTTCTTCAG p.S1152Rfsx3 Sporadic In this study
TCS 12 caucasian 22 c.3700_3704delACTCT p.T1234Gfsx5 Sporadic In this study
TCS 13 caucasian 23B c.4331C > T p.Q1411X Sporadic In this study
TCS 14 caucasian 24 c.4359_4363delAAAAA p.E1453Efsx16 Sporadic [17]
TCS 15
TCS 16
TCS 17
caucasian 24 c.4366_4370delGAAAA p.E1456Efsx13 Familial
Sporadic
Sporadic
[17]
The cDNA major isoform (including exon 6A, but without exon 16A) was deposited in GenBank with accession number AY460334[14].
For the cDNA sequence, nucleotide +1 is the A of the ATG-translation initiation codon.
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It was located in exon 6 and it caused a stop codon 19
codons later.
In 29 patients, with apparently TCS phenotype, no
pathogenic mutations have been identified after screen-
i n go ft h ew h o l ec o d i n gr e g i o no ft h eg e n e .H o w e v e r
these patients present clinical features of the syndrome.
All these cases are isolated.
A large number of TCOF1 polymorphisms were
detected. Thirteen of these were already published and 7
are novel (Table 3). Twelve were silent or missense var-
iation and 8 occur in intronic regions. All novel poly-
morphisms were present in controls in different
percentages.
Patient TCS 21 had a single base substitution c.2859-
30G > A in exon 16. This substitution wasn’ti d e n t i f i e d
in 150 healthy chromosomes; therefore, this variation
could be a novel splicing mutation in the TCOF1 gene.
Computer simulation studies were performed to evalu-
ate the role of this variation in hypothetical splicing
enhancer or splice site prediction, and we deduced that
the mutated sequence determines a loss of SF2/ASF and
S r p 5 5a n dag a i no fS R p 4 0b i n d i n gs i t e s ,b u tt h es a m e
splice site strength score was 0.89, similar to wild type
sequence, according to ESE finder and NNSplice pro-
grams, respectively.
Discussion
In this study, we report the screening of entire TCOF1
coding region and the identification of a spectrum of 3
known mutations, 12 novel pathogenetic mutations and
7 novel polymorphisms by direct sequencing. In all
familial cases, we identified the TCOF1 mutation in one
parent with similar TCS features. Of the 43 analyzed
sporadic cases, 14 had arisen as the result of a de novo
mutations in the TCOF1 gene. The sensitivity of sequen-
cing analysis of TCOF1 gene on our patients was 37%
(17/46). The remaining 29 TCS patients, negative to the
TCOF1 screening, have to be clinically revaluated. In
this regard, we recommend a clinical revaluation using
Figure 1 A-O Chromatograms of characterized pathogenic mutations in TCS patients. The header of each picture indicates the nucleotide
mutation. The arrows show the site of mutation in chromatograms. A and E chromatograms report reverse sequences; B-D and F-O
chromatograms report forward sequences.
Conte et al. BMC Medical Genetics 2011, 12:125
http://www.biomedcentral.com/1471-2350/12/125
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zygomatic hypoplasia as a clinical feature of TCS
patients [19]. On the other hand, the differential diagno-
sis is necessary. In fact, Nager and Miller syndrome
exhibits phenotypic overlap with TCS. Moreover, muta-
tions in genes encoding subunits of RNA polymerases I
and III (POLR1C and POLR1D) cause TCS, too [7]. We
are considering to perform the screening of POLR1C
and POLR1D genes in our negatives TCOF1 patients.
The TCOF1 gene mutations include missense, non-
sense, small deletions and duplications. In particular,
the most common classes of TCOF1 alleles are small
deletions (60%) and duplications (25%) resulting in fra-
meshifts [10]. According to literature data, 76.5% (13/
17) of our characterised mutations are microdeletions
and 6% (1/17) are duplications. Though it has been sug-
gested that five exons (10, 15, 16, 23 and 24), are
defined as a hot spot region of the TCOF1 gene muta-
tions [14], a distribution of pathogenic variations along
all the gene was reported by different authors. We con-
firmed exon 24 as hot spot of the TCOF1 gene as we
described the major number of mutations in the exon
(Table 2 Figure 1). The c.4366_4370delGAAAA is the
most frequent mutation as we found it in three of 16
affected patients. This is probably due to the high
repetition of adenines (60% of exon) making exon 24
region prones to polymerase slippage in DNA replica-
tion [14]. Moreover, the high complexity of this exon
make it difficult to give the right nomenclature to the
identified sequence variations. It is therefore mandatory
to sequence exon 24 in both directions. Also in this
study exons 10, 15, and 16 were revealed as pathogenic
gene regions. Finally, three mutations were found in
rarely affected sequences.
Two more TCOF1 variations were found in patient
TCAR. The presence of two possible TCOF1 mutations
in the same patient has been reported in a paper by
Fujioka H et al. [20]. In this case, familiar analysis is
requested to predict which is the benign and which is
the pathological variation in TCS.
All patients, and in particular patients with typical
TCS features but negative TCOF1 screening, were ana-
lyzed for the two alternatively spliced in-frame exons
(6A and 16A) and no mutations were found.
Conclusion
In this work, the observation of affected features, com-
bined with a molecular analysis, is sufficient to perform
a correct TCS diagnosis in 35% of cases. This is the
phenotypic variability of TCS.
Table 3 Polymorphisms in TCS patients
PATIENT LOCATION cDNA MAJOR
ISOFORM
POLYMORPHISM
AMINOACID
CHANGE
ALLELE
FREQUENCIES
IN CONTROLS
REFERENCE
TCS 8, TCS 18 5’UTR 5’UTR-41G > T None 0.82 In this study
TCS 18 Intron 6 c..639 +32C > G None 0.02 [11]
TCS 19 Exon 7 c.1347T > C p.P439L 0.01 [13]
TCS 6, TCS 11 Exon 10 c.1578 T > C p.P526P 0.77 [13]
TCS 1, TCS 6, TCS 17, TCS 19 Exon 11 c.1761G > T p.G587G 0.10 [11]
TCS 17, TCS 19, TCS 20 Exon 11 c.1842A > G p.S614S 0.52 [13]
TCS 10 Exon 12 1837G > C p.A588P 0.31 In this study
TCS 10, TCS 10.1, TCS 10.3, TCS 11, TCS 20 Exon 12 c.1993C > G p.A665P 0.21 International HapMap
project
TCS10, TCS 11, TCS 20 Intron 15 c.2659-28delTCTC None 0.15 In this study
TCS 13 Exon16 c.2660 C > T p.A887V 0.82 [13]
TCS 19 Exon 16 c.2765 C > T p.S992L 0.01 [13]
TCS 21 Intron 16 c.2859-30G > A None 0.0 In this study
TCS 11, TCS 20 Intron 16A c.2859+3444C > T None 0.05 In this study
TCS 7, Mother carrier Exon 17 c.2924C > T p.P975L 0.0 In this study
TCS 22 Intron 19 c.3197+66C > T None 1.0 International HapMap
project
TCS 13, TCS 19 Intron 20 c.3517-34G > A None 0.1 In this study
TCS 13, TCS 14, TCS19, TCS 23, TCS 24, TCS 25 Exon 21 c.3527C > G p.P1176R 0.16 [11]
TCS 1, TCS 13, TCS 19 Intron 21 c.3370-3C > T None 1.0 [8]
TCS 6, TCS 22, TCS 26, TCS 27, TCS 28,TCS 29, TCS 30,
TCS 31, TCS 32
Exon 23B c.4169C > T p.A1390V 0.24 [11]
TCS 23, TCS 32 Exon 23B C.4292G > C p.G1431A 0.03 [11]
The URL for International HapMap project is http://hapmap.ncbi.nlm.nih.gov/
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